Research progress on treatment of extramedullary multiple myeloma

References

• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Bladé J, de Larrea CF, Rosiñol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805–3812.
   PubMed Web of Science ®Google Scholar
• Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360–364.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127(8):971–976.
   PubMed Web of Science ®Google Scholar
• Batsukh K, Lee SE, Min GJ, et al. Distinct clinical outcomes between paramedullary and extramedullary lesions in newly diagnosed multiple myeloma. Immune Netw. 2017;17(4):250–260.
   PubMed Web of Science ®Google Scholar
• Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–908.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761–1767.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013;54(6):1135–1141.
   PubMed Web of Science ®Google Scholar
• Sevcikova S, Minarik J, Stork M, et al. Extramedullary disease in multiple myeloma – controversies and future directions. Blood Rev. 2019;36:32–39.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–330.
   PubMed Web of Science ®Google Scholar
• Minarik J, Krhovska P, Hrbek J, et al. Prospective comparison of conventional radiography, low-dose computed tomography and magnetic resonance imaging in monoclonal gammopathies. Biomed Pap. 2016;160(2):305–309.
   PubMed Web of Science ®Google Scholar
• Wu F, Bernard S, Fayad LM, et al. Updates and ongoing challenges in imaging of multiple myeloma: AJR expert panel narrative review. Am J Roentgenol. 2021;217(4):775–785.
   PubMed Web of Science ®Google Scholar
• Chen J, Li C, Tian Y, et al. Comparison of whole-body DWI and 18F-FDG PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma. Am J Roentgenol. 2019;213(3):514–523.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Aljawai Y, Morgan EA, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851–858.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Eikema DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT. Haematologica. 2018;103(5):890–897.
   PubMed Web of Science ®Google Scholar
• Bladé J, de Larrea CF, Rosiñol L. Extramedullary involvement in multiple myeloma. Haematologica. 2012;97(11):1618–1619.
   PubMed Web of Science ®Google Scholar
• De Larrea CF, Rosiñol L, Cibeira MT, et al. Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. Eur J Haematol. 2010;85(5):448–451.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, de Larrea CF, Bladé J. Extramedullary myeloma spread triggered by surgical procedures: an emerging entity? Acta Haematol. 2014;132(1):36–38.
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Sureda A, Fernandez-Aviles F, et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia. 2006;20(3):542–545.
   PubMed Web of Science ®Google Scholar
• Minnema MC, van de Donk NW, Zweegman S, et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant. 2008;41(9):779–784.
   PubMed Web of Science ®Google Scholar
• Raanani P, Shpilberg O, Ben-Bassat I. Extramedullary disease and targeted therapies in haematological malignancies – is the association real? Ann Oncol. 2007;18(1):7–12.
   PubMed Web of Science ®Google Scholar
• Varga C, Xie W, Laubach J, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169(6):843–850.
   PubMed Web of Science ®Google Scholar
• Vincent L, Ceballos P, Plassot C, et al. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Blood Cancer J. 2015;5(8):e341.
   PubMedGoogle Scholar
• Lonial S, Boise LH, Kaufman J. How I treat high-risk myeloma. Blood. 2015;126(13):1536–1543.
   PubMed Web of Science ®Google Scholar
• Mangiacavalli S, Pompa A, Ferretti V, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96(1):73–80.
   PubMed Web of Science ®Google Scholar
• Perrot A, Facon T, Plesner T, et al. Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial. J Clin Oncol. 2021;39(3):227–237.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801–812.
   PubMed Web of Science ®Google Scholar
• Park JE, Miller Z, Jun Y, et al. Next-generation proteasome inhibitors for cancer therapy. Transl Res. 2018;198:1–16.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Cibeira MT, Uriburu C, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76(5):405–408.
   PubMed Web of Science ®Google Scholar
• Patriarca F, Prosdocimo S, Tomadini V, et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica. 2005;90(2):278–279.
   PubMed Web of Science ®Google Scholar
• Paubelle E, Coppo P, Garderet L, et al. Complete remission with bortezomib on plasmacytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia. 2005;19(9):1702–1704.
   PubMed Web of Science ®Google Scholar
• Lee SE, Kim JH, Jeon YW, et al. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol. 2015;94(3):445–452.
   PubMed Web of Science ®Google Scholar
• Lakshman A, Singh PP, Rajkumar SV, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed refractory multiple myeloma. Am J Hematol. 2018;93(2):179–186.
   PubMed Web of Science ®Google Scholar
• Dingli D, Ailawadhi S, Bergsagel PL, et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc. 2017;92(4):578–598.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138(2):176–185.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Ram R, Raanani P, et al. First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience. Leuk Res. 2014;38(12):1401–1406.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Fonseca R, Siegel D, et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128(9):1174–1180.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Goldschmidt H, Dimopoulos MA, et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017;31(6):1368–1374.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Wang M, Maisnar V, et al. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018;11(1):49.
   PubMedGoogle Scholar
• Muchtar E, Gatt ME, Rouvio O, et al. Efficacy and safety of salvage therapy using carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br J Haematol. 2016;172(1):89–96.
   PubMed Web of Science ®Google Scholar
• Español I, Romera M, Gutiérrez-Meca MD, et al. Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement. Clin Case Rep. 2017;5(8):1258–1260.
   PubMed Web of Science ®Google Scholar
• Zhou X, Flüchter P, Nickel K, et al. Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma With extramedullary disease. Cancers (Basel). 2020;12(4):1035.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–2962.
   PubMed Web of Science ®Google Scholar
• Biagi JJ, Prince HM. Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation. Br J Haematol. 2001;115(2):484–485.
   PubMed Web of Science ®Google Scholar
• Bladé J, Perales M, Rosiñol L, et al. Thalidomide in multiple myeloma: lack of response of soft tissue plasmacytomas. Br J Haematol. 2001;113(2):422–424.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Cibeira MT, Bladé J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832–836.
   PubMed Web of Science ®Google Scholar
• Calvo-Villas JM, Alegre A, Calle C, et al. Lenalidomide is effffective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol. 2011;87(3):281–284.
   PubMed Web of Science ®Google Scholar
• Sher T, Miller KC, Deeb G, et al. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol. 2010;150(4):418–427.
   PubMed Web of Science ®Google Scholar
• Alegre A, Aguado B, Giraldo P, et al. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish compassionate use registry in advanced patients. Int J Hematol. 2011;93(3):351–360.
   PubMed Web of Science ®Google Scholar
• Ito C, Aisa Y, Mihara A, et al. Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases. Clin Lymphoma Myeloma Leuk. 2013;13(1):83–85.
   PubMed Web of Science ®Google Scholar
• Avivi I, Cohen YC, Suska A, et al. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol. 2019;94(10):1132–1140.
   PubMed Web of Science ®Google Scholar
• Hagihara M, Ide S, Ohara S, et al. Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions. Rinsho Ketsueki. 2020;61(1):20–26.
   PubMedGoogle Scholar
• Mussetti A, Dalto S, Montefusco V. Effective treatment of pomalidomide in central nervous system myelomatosis. Leuk Lymphoma. 2013;54(4):864–866.
   PubMed Web of Science ®Google Scholar
• Montefusco V, Gay F, Spada S, et al. Outcome Of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica. 2020;105(1):193–200.
   PubMed Web of Science ®Google Scholar
• Jiménez-Segura R, Granell M, Gironella M, et al. Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed/refractory multiple myeloma. Eur J Haematol. 2019;102(5):389–394.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
   PubMed Web of Science ®Google Scholar
• Shah NN, Maatman T, Hari P, et al. Multi targeted CAR-T cell therapies for B-cell malignancies. Front Oncol. 2019;9(146).
   Google Scholar
• Ackley J, Ochoa MA, Ghoshal D, et al. Keeping myeloma in check: the past. present and future of immunotherapy in multiple myeloma. Cancers (Basel. 2021;13(19):4787.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. J Clin Invest. 2016;126(7):2588–2596.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Maus MV, Hwang WT, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040–1047.
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Lin Y, Raje N, et al. Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-bcma CAR T cell therapy. Blood. 2017;130(740). (abstr).
   Google Scholar
• Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267–2280.
   PubMed Web of Science ®Google Scholar
• Bazarbachi AH, Hamed R AI, Malard F, et al. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33(10):2343–2357.
   PubMed Web of Science ®Google Scholar
• Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CART-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci USA. 2019;116(19):9543–9551.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Richardson PG, Anderson KC. Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014;32(20):2125–2132.
   PubMed Web of Science ®Google Scholar
• Li J, Shen KN, Huang WR, et al. Autologous stem cell transplant can overcome poor prognosis in patients with multiple myeloma with extramedullary plasmacytoma. Leuk Lymphoma. 2014;55(7):1687–1690.
   PubMed Web of Science ®Google Scholar
• Kumar L, Gogi R, Patel AK, et al. Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transpl. 2017;52(10):1473–1475.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Eikema DJ, Koster L, et al. Tandem autologous stem cell transplantation improves outcome in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the chronic malignancies working party of EBMT. Biol Blood Marrow Transplant. 2019;25(11):2134–2142.
   PubMed Web of Science ®Google Scholar
• Beksac M, Cengiz Seval G, Kanellias N, et al. A real world multicenter retrospective study on extramedullary disease from Balkan myeloma study group and Barcelona university: analysis of parameters that improve outcome. Haematologica. 2020;105(1):201–208.
   PubMed Web of Science ®Google Scholar
• Yin X, Tang L, Fan F, et al. Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017. Cancer Cell Int. 2018;18(62.
   Google Scholar
• Rasche L, Rollig C, Stuhler G, et al. Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease and high risk cytogenetic features. Biol Blood Marrow Transplant. 2016;22(11):1988–1996.
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–320.
   PubMed Web of Science ®Google Scholar
• Jansen JHM, Boross P, Overdijk MB, et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood. 2012;120(21):2974, (abstr).
   Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560.
   PubMed Web of Science ®Google Scholar
• Minarik J, Pour L, Maisnar V, et al. Single agent daratumumab in advanced multiple myeloma: specific healthcare program in the Czech Republic. Blood. 2017;130:5414.
   Web of Science ®Google Scholar
• Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37–44.
   PubMed Web of Science ®Google Scholar
• Pick M, Vainstein V, Goldschmidt N, et al. Daratumumab resistance is frequent in advanced stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. Eur J Haematol. 2018;100(5):494–501.
   PubMed Web of Science ®Google Scholar
• Kashima E, Fujieda A, Nato Y, et al. Successful treatment With a combination of elotuzumab, lenalidomide and dexamethasone of extramedullary disease in a patient With refractory multiple myeloma. Rinsho Ketsueki. 2020;61(3):223–227.
   PubMedGoogle Scholar